Skip to main content

Table 7 Associations between the use of infliximab and patient, disease and treatment characteristics for patients with Crohn's disease (n = 1787)

From: A national survey on the patterns of treatment of inflammatory bowel disease in Canada

Characteristics % Reporting Infliximab Odds ratio 95% CI
Sex    
   Male 5.5 Referent  
   Female 5.6 1.0 0.7 to 1.6
Age    
   16–24 11.6 Referent  
   25–40 7.7 0.6 0.3 to 1.3
   41–55 4.8 0.4 0.2 to 0.8
   >55 2.7 0.2 0.1 to 0.5
Disease activity    
   Inactive 1.8 Referent  
   Mild 2.3 1.3 0.5 to 3.3
   Moderate 5.4 3.0 1.3 to 7.4
   Severe 21.1 14.4 5.7 to 36.3
Prior hospitalization    
   No 1.7 Referent  
   Yes 6.3 3.9 1.6 to 9.6
Surgery within the past 2 years    
   No 4.6 Referent  
   Yes 11.4 2.7 1.7 to 4.2
IV Steroids in past 12 months    
   No 4.8 Referent  
   Yes 18.9 4.6 2.6 to 8.2
PO Steroids in past 12 months    
   No 2.5 Referent  
   Yes 11.2 5.0 3.2 to 7.8
PO 6 MP/Azathioprine in past 12 months    
   No 3.6 Referent  
   Yes 11.8 3.6 2.4 to 5.4